Albendazole ivermectin nano preparation and preparation method thereof

By optimizing the group distribution ratio and process parameters, using tannic acid, sodium phytate and sodium dodecylbenzenesulfonate as dispersants, an albendazole ivermectin nanoformula with a particle size of 30-80 nm was prepared. , solves the particle size and dispersion of albendazole ivermectin nano powder in traditional methods, and significantly improves solubility and insecticidal effect.

CN118453635BActive Publication Date: 2024-11-01INSTITUTE OF ENVIRONMENT AND SUSTAINABLE DEVELOPMENT IN AGRICULTURE CAAS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410932412.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-12
Publication Date
2024-11-01
Estimated Expiration
2044-07-12

AI Technical Summary

Technical Problem

The existing technology is difficult to prepare albendazole ivermectin nano preparations with small particle size, uniform particle dispersion and good solubility. The traditional anti-solvent method is prone to crystallization, precipitation and agglomeration problems during the preparation process, which affects the drug. Particle size and morphology lead to poor solubility and efficacy.

Method used

Tannic acid, sodium phytate and sodium dodecylbenzenesulfonate were used as dispersants, by mixing albendazole and ivermectin at room temperature and adding solvents and solubilizers, followed by dropping under shearing conditions Add to the dispersant, centrifugation and freeze-drying, optimize the distribution ratio and process parameters to prepare albendazole ivermectin nanoformulations with particle sizes of 30-80 nm.

Benefits of technology

The prepared albendazole ivermectin nanoformula has a smaller particle size, improves fluidity and solubility, significantly improves bioavailability and insecticidal effect, and has good storage stability, which is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118453635B_ABST
    Figure CN118453635B_ABST
Patent Text Reader

Abstract

The invention provides an albendazole ivermectin nano preparation and a preparation method thereof, which is composed of the following components by weight: 10 parts of albendazole, 0.3-1 parts of ivermectin and 53-111 parts of a dispersant, wherein the dispersant is a mixture of tannic acid, sodium phytate and sodium dodecylbenzene sulfonate, and in the dispersant, the weight ratio of tannic acid, sodium phytate and sodium dodecylbenzene sulfonate is 30-90:1-10:20. The albendazole ivermectin nano preparation prepared by the invention has a small particle size, uniform particle dispersion, a simple preparation method, and good solubility, stability and insecticidal effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of veterinary preparations, and in particular to an albendazole ivermectin nano preparation and a preparation method thereof. Background Art

[0002] Albendazole and ivermectin are commonly used antiparasitic drugs in veterinary clinics. However, due to the low solubility of these two drugs, their absorption and utilization in animals are limited. Although traditional drug preparation technologies such as micronization, suspension or suspension preparation can improve the solubility and bioavailability of drugs to a certain extent, the effect is limited. In order to solve these problems, researchers began to explore the preparation methods of nanomedicines. Nanomedicine is a new type of drug preparation in which the drug ingredients are nano-scale particles. Since nanoparticles have the characteristics of high specific surface area, high biological activity, high solubility, and high stability, nanomedicine can improve the bioavailability of drugs, enhance the efficacy, and reduce the dosage and side effects of drugs.

[0003] The antisolvent method is a commonly used chemical method for preparing nano drugs. Its principle is to quickly mix, disperse or spray the drug solution into the antisolvent, and control the particle size and morphology of the nanoparticles by controlling the ratio of the solvent and the antisolvent, the mixing speed, the temperature and other parameters. Although the antisolvent method has certain advantages in the preparation of nano drugs, there are still some technical difficulties in the preparation of albendazole and ivermectin nano powders. For example, the solubility of albendazole and ivermectin is low, and crystallization and precipitation are prone to occur during the preparation process; at the same time, when using the antisolvent method to prepare nano powder drugs, problems such as agglomeration and wall adhesion are prone to occur, which affects the particle size and morphology of the nanoparticles, resulting in problems such as large particle size, uneven particle dispersion, poor solubility and efficacy of the prepared drug preparations.

[0004] Therefore, how to use the anti-solvent method to prepare albendazole ivermectin nanoformulations with smaller particle size, uniform particle dispersion, better solubility and efficacy has become an urgent problem to be solved in the field. Summary of the invention

[0005] In view of the above problems, an object of the present invention is to provide an albendazole ivermectin nanoformulation and a preparation method thereof. The albendazole ivermectin nanoformulation prepared by the present invention has a small particle size and uniform particle dispersion, and the preparation method is simple, and has good solubility, stability and insecticidal effect.

[0006] Another object of the present invention is to provide a method for preparing the albendazole-ivermectin nanoformulation.

[0007] In order to achieve the above object, the present invention provides an albendazole ivermectin nano preparation, which is composed of the following components by weight:

[0008] Albendazole: 10 parts

[0009] Ivermectin: 0.3-1 part

[0010] Dispersant: 53-111 parts

[0011] Among them, albendazole and ivermectin account for 8.87-16.27% of the total weight of the albendazole ivermectin nano preparation, and the dispersant is a mixture of tannic acid, sodium phytate and sodium dodecylbenzene sulfonate. In the dispersant, the weight ratio of tannic acid, sodium phytate and sodium dodecylbenzene sulfonate is 30-90:1-10:20.

[0012] In some embodiments, the albendazole ivermectin nanoformulation consists of the following components by weight:

[0013] Albendazole: 10 parts

[0014] Ivermectin: 0.5-0.8 parts

[0015] Dispersant: 80-111 parts

[0016] Among them, albendazole and ivermectin account for 8.87-12.09% of the total weight of the albendazole ivermectin nano preparation, and in the dispersant, the weight ratio of tannic acid, sodium phytate and sodium dodecylbenzene sulfonate is 50-70:3-7:20.

[0017] In some embodiments, the albendazole ivermectin nanoformulation consists of the following components by weight:

[0018] Albendazole: 10 parts

[0019] Ivermectin: 0.7 parts

[0020] Dispersant: 90 parts

[0021] Among them, albendazole and ivermectin account for 10.63% of the total weight of the albendazole ivermectin nano preparation, and in the dispersant, the weight ratio of tannic acid, sodium phytate and sodium dodecylbenzene sulfonate is 65:5:20.

[0022] In some embodiments, the albendazole-ivermectin nanoformulation is a water-soluble powder with a particle size of 30-80 nm.

[0023] The present invention further provides a method for preparing the albendazole ivermectin nanoformulation as described above, the preparation method comprising the following steps:

[0024] Step a: at room temperature, albendazole and ivermectin are mixed, then added into a solvent to dissolve, and a solubilizing agent is added to obtain a mixed solution A;

[0025] Step b: dissolving the dispersant in water to obtain a mixed solution B;

[0026] Step c: under shear conditions, adding the mixed solution A dropwise to the mixed solution B to obtain a mixed solution C;

[0027] Step d: centrifuging and drying the mixed solution C to obtain an albendazole-ivermectin nanoformulation.

[0028] In some embodiments, the solvent in step a is anhydrous ethanol or γ-valerolactone, the solubilizer is glacial acetic acid, the concentration of albendazole in the mixed solution A is 0.071-0.125 g / mL; the concentration of ivermectin in the mixed solution A is 0.0038-0.0071 g / mL;

[0029] The concentration of the dispersant in the mixed solution B is 0.106-0.222 g / mL.

[0030] In some embodiments, the concentration of albendazole in the mixed solution A is 0.091 g / mL; the concentration of ivermectin in the mixed solution A is 0.0064 g / mL;

[0031] The concentration of the dispersant in the mixed solution B is 0.180 g / mL.

[0032] In some embodiments, step c comprises: using a high-speed shearing machine to shear the mixed solution B at 10000-15000 rpm for 5 min, and at the same time, dripping the mixed solution A into the mixed solution B at a rate of 2 mL / min;

[0033] The step d comprises: subjecting the mixed solution C to high-speed centrifugation at a speed of 8000-12000 rpm for 20 min to obtain a precipitate, and freeze-drying the precipitate at -30°C to -50°C for 48-96 h to obtain an albendazole ivermectin nanoformulation.

[0034] In some embodiments, step c comprises: using a high-speed shearing machine to shear the mixed solution B at 11000-14000 rpm for 5 min, and at the same time, dripping the mixed solution A into the mixed solution B at a rate of 2 mL / min;

[0035] The step d comprises: subjecting the mixed solution C to high-speed centrifugation at a speed of 10000-12000 rpm for 20 min to obtain a precipitate, and freeze-drying the precipitate at -35°C to -45°C for 60-80 h to obtain an albendazole ivermectin nano preparation.

[0036] In some embodiments, step c comprises: using a high-speed shearing machine to shear the mixed solution B at 12,000 rpm for 5 min, and at the same time, dripping the mixed solution A into the mixed solution B at a rate of 2 mL / min;

[0037] The step d comprises: subjecting the mixed solution C to high-speed centrifugation at a speed of 12,000 rpm for 20 minutes to obtain a precipitate, and freeze-drying the precipitate at -45°C for 72 hours to obtain an albendazole ivermectin nanoformulation.

[0038] The present invention obtains suitable solvents and dispersants for preparing albendazole ivermectin pharmaceutical preparations through experimental screening, and optimizes the component ratio and preparation process parameters to prepare albendazole ivermectin nano preparations. Compared with the existing albendazole ivermectin preparations, the albendazole ivermectin nano preparation provided by the present invention has the following advantages:

[0039] 1. The present invention optimizes the components and their ratios as well as the preparation process parameters, so that the particle size of the prepared albendazole ivermectin nanoformulation can reach 30-80 nm, thereby having a smaller particle size than the existing products, improving the fluidity and solubility of the product, and facilitating the realization of industrial production;

[0040] 2. The albendazole ivermectin nanoformulation prepared by the present invention has almost no change in particle size after being stored at room temperature, 30°C and 65% relative humidity for 3 months, and has good storage stability;

[0041] 3. The albendazole ivermectin nanoformulation prepared by the present invention is a soluble powder, which has significantly higher solubility than the existing albendazole ivermectin preparations, and greatly improves the solubility of the albendazole ivermectin preparations;

[0042] 4. The main pharmacokinetic parameters of the albendazole ivermectin nanoformulation of the present invention are significantly better than those of commercially available preparations, and the bioavailability is high, and it has a better therapeutic effect than commercially available preparations;

[0043] 5. The insecticidal effect of the albendazole-ivermectin nanoformulation of the present invention on Caenorhabditis elegans is significantly better than that of commercially available preparations, and has a good insecticidal effect;

[0044] 6. The preparation method of the present invention is simple, easy to operate, low in cost, and can be industrialized and mass-produced. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 A transmission electron microscope image of the albendazole ivermectin nanoformulation prepared by the present invention is shown;

[0046] Figure 2The particle size distribution diagram of the albendazole ivermectin nanoformulation prepared by the present invention is shown;

[0047] Figure 3 The solution state of the albendazole ivermectin nanoformulation prepared by the present invention and the existing albendazole ivermectin preparation after being dissolved in water is shown;

[0048] Figure 4 Shown are adult C. elegans after 3 days of culture;

[0049] Figure 5 The live Caenorhabditis elegans ( Figure 5 A) and dead C. elegans ( Figure 5 B) Comparison pictures;

[0050] Figure 6 The Caenorhabditis elegans lethality of the albendazole ivermectin nanoformulation solutions of the present invention at different concentrations is shown;

[0051] Figure 7 Shown is a comparison of Caenorhabditis elegans lethality of different formulations. DETAILED DESCRIPTION

[0052] The present invention is described below with reference to specific examples. It will be appreciated by those skilled in the art that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention in any way.

[0053] The experimental methods in the following examples are conventional methods unless otherwise specified. The pharmaceutical raw materials, reagent materials, etc. used in the following examples are commercially available products unless otherwise specified.

[0054] Example 1, preparation of albendazole ivermectin nanoformulation 1: At room temperature, 10.0 g of albendazole and 0.3 g of ivermectin were mixed, then added to 20 mL of solvent anhydrous ethanol to dissolve, and 60 mL of solubilizing agent glacial acetic acid was added to obtain a mixed solution A; in the mixed solution A, the concentration of albendazole was 0.125 g / mL, and the concentration of ivermectin was 0.0038 g / mL.

[0055] Dispersants 30 g of tannic acid, 3 g of sodium phytate and 20 g of sodium dodecylbenzene sulfonate were dissolved in 500 mL of water to obtain a mixed solution B; in the mixed solution B, the total concentration of the dispersants was 0.106 g / mL.

[0056] The mixed solution B was sheared at 12000 rpm for 5 min using a high-speed shearing machine, and the mixed solution A was added dropwise to the mixed solution B at a rate of 2 mL / min;

[0057] The mixed solution C was centrifuged at a speed of 11000 rpm for 20 min to obtain a precipitate, and the precipitate was freeze-dried at -30°C for 72 h to obtain an albendazole ivermectin nanoformulation.

[0058] Example 2, preparation of albendazole ivermectin nanoformulation 2: At room temperature, 10.0 g of albendazole and 0.7 g of ivermectin were mixed, then added to 50 mL of solvent anhydrous ethanol to dissolve, and 60 mL of solubilizing agent glacial acetic acid was added to obtain a mixed solution A; in the mixed solution A, the concentration of albendazole was 0.091 g / mL, and the concentration of ivermectin was 0.0064 g / mL.

[0059] Dispersants 65 g of tannic acid, 5 g of sodium phytate and 20 g of sodium dodecylbenzene sulfonate were dissolved in 500 mL of water to obtain a mixed solution B; in the mixed solution B, the total concentration of the dispersants was 0.180 g / mL.

[0060] The mixed solution B was sheared at 12000 rpm for 5 min using a high-speed shearing machine, and the mixed solution A was added dropwise to the mixed solution B at a rate of 2 mL / min;

[0061] The mixed solution C was centrifuged at a speed of 12000 rpm for 20 min to obtain a precipitate, and the precipitate was freeze-dried at -45°C for 80 h to obtain an albendazole ivermectin nanoformulation.

[0062] Example 3, preparation of albendazole ivermectin nanoformulation 3: At room temperature, 10.0 g of albendazole and 1.0 g of ivermectin were mixed, then added to 80 mL of solvent anhydrous ethanol to dissolve, and 60 mL of solubilizing agent glacial acetic acid was added to obtain a mixed solution A; in the mixed solution A, the concentration of albendazole was 0.071 g / mL, and the concentration of ivermectin was 0.0071 g / mL.

[0063] Dispersants 50 g of tannic acid, 10 g of sodium phytate and 20 g of sodium dodecylbenzene sulfonate were dissolved in 500 mL of water to obtain a mixed solution B; in the mixed solution B, the total concentration of the dispersants was 0.160 g / mL.

[0064] The mixed solution B was sheared at 14000 rpm for 5 min using a high-speed shearing machine, and the mixed solution A was added dropwise to the mixed solution B at a rate of 2 mL / min;

[0065] The mixed solution C was centrifuged at a speed of 12000 rpm for 20 min to obtain a precipitate, and the precipitate was freeze-dried at -50°C for 85 h to obtain an albendazole ivermectin nanoformulation.

[0066] Example 4, preparation of albendazole ivermectin nanoformulation 4: At room temperature, 10.0 g of albendazole and 0.5 g of ivermectin were mixed, then added to 60 mL of solvent anhydrous ethanol to dissolve, and 60 mL of solubilizing agent glacial acetic acid was added to obtain a mixed solution A; in the mixed solution A, the concentration of albendazole was 0.083 g / mL, and the concentration of ivermectin was 0.0042 g / mL.

[0067] Dispersants 60 g of tannic acid, 5 g of sodium phytate and 20 g of sodium dodecylbenzene sulfonate were dissolved in 500 mL of water to obtain a mixed solution B; in the mixed solution B, the total concentration of the dispersants was 0.170 g / mL.

[0068] The mixed solution B was sheared at 11000 rpm for 5 min using a high-speed shearing machine, and the mixed solution A was added dropwise to the mixed solution B at a rate of 2 mL / min;

[0069] The mixed solution C was centrifuged at a speed of 10000 rpm for 20 min to obtain a precipitate, and the precipitate was freeze-dried at -45°C for 60 h to obtain an albendazole ivermectin nanoformulation.

[0070] Example 5, preparation of albendazole ivermectin nanoformulation 5: At room temperature, 10.0 g of albendazole and 0.8 g of ivermectin were mixed, then added to 60 mL of solvent anhydrous ethanol to dissolve, and 60 mL of solubilizing agent glacial acetic acid was added to obtain a mixed solution A; in the mixed solution A, the concentration of albendazole was 0.083 g / mL, and the concentration of ivermectin was 0.0067 g / mL.

[0071] Dispersants 90 g of tannic acid, 1 g of sodium phytate and 20 g of sodium dodecylbenzene sulfonate were dissolved in 500 mL of water to obtain a mixed solution B; in the mixed solution B, the total concentration of the dispersants was 0.222 g / mL.

[0072] The mixed solution B was sheared at 12000 rpm for 5 min using a high-speed shearing machine, and the mixed solution A was added dropwise to the mixed solution B at a rate of 2 mL / min;

[0073] The mixed solution C was centrifuged at a speed of 11000 rpm for 20 min to obtain a precipitate, and the precipitate was freeze-dried at -45°C for 96 h to obtain an albendazole ivermectin nanoformulation.

[0074] Example 6, preparation of albendazole ivermectin nanoformulation 6: At room temperature, 10.0 g of albendazole and 0.6 g of ivermectin were mixed, then added to 70 mL of γ-valerolactone solvent to dissolve, and 60 mL of solubilizing agent glacial acetic acid was added to obtain a mixed solution A; in the mixed solution A, the concentration of albendazole was 0.077 g / mL, and the concentration of ivermectin was 0.0046 g / mL.

[0075] Dispersants 70 g of tannic acid, 3 g of sodium phytate and 20 g of sodium dodecylbenzene sulfonate were dissolved in 500 mL of water to obtain a mixed solution B; in the mixed solution B, the total concentration of the dispersants was 0.186 g / mL.

[0076] The mixed solution B was sheared at 15000 rpm for 5 min using a high-speed shearing machine, and the mixed solution A was added dropwise to the mixed solution B at a rate of 2 mL / min;

[0077] The mixed solution C was centrifuged at a speed of 12000 rpm for 20 min to obtain a precipitate, and the precipitate was freeze-dried at -40°C for 60 h to obtain an albendazole ivermectin nanoformulation.

[0078] Example 7, preparation of albendazole ivermectin nanoformulation 7: At room temperature, 10.0 g of albendazole and 0.4 g of ivermectin were mixed, then added to 30 mL of solvent γ-valerolactone to dissolve, and 60 mL of solubilizing agent glacial acetic acid was added to obtain a mixed solution A; in the mixed solution A, the concentration of albendazole was 0.111 g / mL, and the concentration of ivermectin was 0.0044 g / mL.

[0079] Dispersants 60 g of tannic acid, 7 g of sodium phytate and 20 g of sodium dodecylbenzene sulfonate were dissolved in 500 mL of water to obtain a mixed solution B; in the mixed solution B, the total concentration of the dispersants was 0.174 g / mL.

[0080] The mixed solution B was sheared at 10000 rpm for 5 min using a high-speed shearing machine, and the mixed solution A was added dropwise to the mixed solution B at a rate of 2 mL / min;

[0081] The mixed solution C was centrifuged at a speed of 10000 rpm for 20 min to obtain a precipitate, and the precipitate was freeze-dried at -35°C for 72 h to obtain an albendazole ivermectin nanoformulation.

[0082] Example 8, preparation of albendazole ivermectin nanoformulation 8: At room temperature, 10.0 g of albendazole and 0.6 g of ivermectin were mixed, then added to 50 mL of solvent γ-valerolactone to dissolve, and 60 mL of solubilizing agent glacial acetic acid was added to obtain a mixed solution A; in the mixed solution A, the concentration of albendazole was 0.091 g / mL, and the concentration of ivermectin was 0.0055 g / mL.

[0083] Dispersants 65 g of tannic acid, 6 g of sodium phytate and 20 g of sodium dodecylbenzene sulfonate were dissolved in 500 mL of water to obtain a mixed solution B; in the mixed solution B, the total concentration of the dispersants was 0.182 g / mL.

[0084] The mixed solution B was sheared at 11000 rpm for 5 min using a high-speed shearing machine, and the mixed solution A was added dropwise to the mixed solution B at a rate of 2 mL / min;

[0085] The mixed solution C was centrifuged at a speed of 8000 rpm for 20 min to obtain a precipitate, and the precipitate was freeze-dried at -50°C for 48 h to obtain an albendazole ivermectin nanoformulation.

[0086] Example 9, preparation of albendazole ivermectin nanoformulation 9: At room temperature, 10.0 g of albendazole and 0.7 g of ivermectin were mixed, then added to 50 mL of solvent anhydrous ethanol to dissolve, and 60 mL of solubilizing agent glacial acetic acid was added to obtain a mixed solution A; in the mixed solution A, the concentration of albendazole was 0.091 g / mL, and the concentration of ivermectin was 0.0064 g / mL.

[0087] Dispersants 65 g of tannic acid, 5 g of sodium phytate and 20 g of sodium dodecylbenzene sulfonate were dissolved in 500 mL of water to obtain a mixed solution B; in the mixed solution B, the total concentration of the dispersants was 0.180 g / mL.

[0088] The mixed solution B was sheared at 12000 rpm for 5 min using a high-speed shearing machine, and the mixed solution A was added dropwise to the mixed solution B at a rate of 2 mL / min;

[0089] The mixed solution C was centrifuged at a speed of 12000 rpm for 20 min to obtain a precipitate, and the precipitate was freeze-dried at -45°C for 72 h to obtain an albendazole ivermectin nanoformulation.

[0090] Example 10, preparation of albendazole ivermectin nanoformulation 10: At room temperature, 10.0 g of albendazole and 0.7 g of ivermectin were mixed, then added to 50 mL of γ-valerolactone solvent for dissolution, and 60 mL of solubilizing agent glacial acetic acid was added to obtain a mixed solution A; in the mixed solution A, the concentration of albendazole was 0.091 g / mL, and the concentration of ivermectin was 0.0064 g / mL.

[0091] Dispersants 65 g of tannic acid, 5 g of sodium phytate and 20 g of sodium dodecylbenzene sulfonate were dissolved in 500 mL of water to obtain a mixed solution B; in the mixed solution B, the total concentration of the dispersants was 0.180 g / mL.

[0092] The mixed solution B was sheared at 12000 rpm for 5 min using a high-speed shearing machine, and the mixed solution A was added dropwise to the mixed solution B at a rate of 2 mL / min;

[0093] The mixed solution C was centrifuged at a speed of 12000 rpm for 20 min to obtain a precipitate, and the precipitate was freeze-dried at -45°C for 72 h to obtain an albendazole ivermectin nanoformulation.

[0094] Test 1, surface morphology test: A transmission electron microscope (HITACHI, HT7700) was used to observe the surface morphology of the albendazole ivermectin nanoformulation prepared in Example 9 of the present invention. A laser nanoparticle size analyzer (Malvern, ZETASIZER PRO) was used to test the particle size distribution of the albendazole ivermectin nanoformulation prepared in Example 9 of the present invention.

[0095] Figure 1 The transmission electron microscope image of the albendazole ivermectin nanoformulation prepared by the present invention is shown. It can be seen from the image that the particle size of the albendazole ivermectin nanoformulation prepared by the present invention is relatively small, within the range of 30-80 nm. Figure 2 The particle size distribution diagram of the albendazole ivermectin nanoformulation prepared by the present invention is shown. It can be seen from the figure that the particle size of the albendazole ivermectin nanoformulation prepared by the present invention is mainly distributed at around 70 nm, which is basically consistent with the particle size tested by transmission electron microscopy.

[0096] Test 2, solubility test: 1 g of the albendazole ivermectin nanoformulation prepared in Example 9 of the present invention, the albendazole ivermectin preparation without nano-treatment (the composition ratio is the same as that in Example 9 of the present invention, and the preparation components are directly mixed and prepared without high-speed shearing and high-speed centrifugation), and the albendazole ivermectin preparation prepared according to the scheme of patent CN103800354A (Prescription 1 in paragraph

[0013] of the specification) were respectively put into a beaker, 200 ml of water was added, and the solution was poured into a vial after stirring and photographed.

[0097] Figure 3 The albendazole ivermectin nanoformulation prepared by the present invention is shown Figure 3 A) Albendazole-ivermectin preparation without nano-treatment ( Figure 3 B) and the albendazole ivermectin preparation prepared according to patent CN103800354A ( Figure 3 C) Solution state after dissolving in water. As can be seen from the figure, at a concentration of 5 g / L, the albendazole ivermectin nanoformulation prepared by the present invention is completely dissolved to form a transparent solution without precipitation. The albendazole ivermectin preparation with the same component ratio as the present invention but not subjected to nano-treatment is not completely dissolved, the solution is slightly turbid, and there are more drug precipitations above the solution, while the albendazole ivermectin preparation prepared according to patent CN103800354A cannot be completely dissolved, the solution is very turbid, and there are more drug precipitations above the solution. It can be seen that, relative to the existing albendazole ivermectin preparation, the albendazole ivermectin nanoformulation of the present invention has significantly higher solubility, indicating that the present invention greatly improves the solubility of the albendazole ivermectin preparation by optimizing the component ratio and nano-parameters.

[0098] Test 3, stability test: 1 g of the albendazole ivermectin nanoformulation prepared in Example 9 of the present invention was dissolved in 200 ml of water, and stored for 3 months at room temperature and under accelerated test conditions (30°C, 65% relative humidity), and the changes in the particle size Dv(50) and Dv(90) of the sample were detected using a laser nanoparticle size analyzer (Malvern, ZETASIZER PRO). The test results are shown in Table 1.

[0099] Note: Dv(50), Dv(90) and Z-mean provide information about the particle size distribution and average size of the sample from different perspectives. Dv(50) and Dv(90) represent the cumulative values ​​under the particle size volume distribution, indicating the percentage of particles smaller than a specific particle size value in the sample in the total volume of the total sample, that is, the particle size values ​​of 50% and 90% of the sample volume in the sample. Z-mean represents the average size of the particle population.

[0100] As can be seen from Table 1, the particle size of the albendazole ivermectin nanoformulation of the present invention has almost no change after storage for 3 months at room temperature, 30°C and 65% relative humidity, and the particles have not agglomerated, and there is almost no difference from the state before storage, indicating that the albendazole ivermectin nanoformulation of the present invention has good storage stability.

[0101] Test 4, insecticidal effect test: 1) Experimental subject culture: The present invention selects the C. elegans N2 strain as the experimental subject, hatches the C. elegans fertilized eggs on NGM solid culture medium and cultured for 3 days, and develops into young adults (such as Figure 4 The nematodes were cultured at 20°C.

[0102] 2) Insecticidal effect test of different concentrations of albendazole ivermectin nanoformulations of the present invention: The albendazole ivermectin nanoformulation prepared in Example 9 of the present invention was dissolved in water and prepared into solutions with concentrations of 0.015625 mg / mL, 0.03125 mg / mL, 0.0625 mg / mL, 0.125 mg / mL, 0.25 mg / mL, 0.5 mg / mL and 1 mg / mL (the concentration difference was 2 times), and then the albendazole ivermectin nanoformulation solutions of different concentrations were added to the wells of a 24-well plate, 60 μL of the preparation was added to each well, and 1.5 mL of M9 buffer was added to the wells as a control, 30 Caenorhabditis elegans adults were added to each well, 3 wells for each concentration, and after culturing for 24 hours, the Caenorhabditis elegans lethality of the albendazole ivermectin nanoformulation solutions of different concentrations was counted (the pictures of live Caenorhabditis elegans and dead Caenorhabditis elegans in the experiment are shown in the figure below). Figure 5 A and Figure 5 B). The experimental results are shown in Table 2 and Figure 6 shown.

[0103] From Table 2 and Figure 6 It can be seen that the Caenorhabditis elegans cultured in the albendazole-ivermectin nanoformulations at concentrations of 0.015625 mg / mL, 0.03125 mg / mL, 0.0625 mg / mL and 0.125 mg / mL all survived, with a mortality rate of 0%. The mortality rates of Caenorhabditis elegans cultured in the albendazole-ivermectin nanoformulations at concentrations of 0.25 mg / mL, 0.5 mg / mL and 1 mg / mL were 1%, 24.80% and 94.90%, respectively. It can be seen that the albendazole-ivermectin nanoformulation has the best insecticidal effect on Caenorhabditis elegans at a concentration of 1 mg / mL.

[0104] 3) Comparison of the insecticidal effects of the albendazole ivermectin nanoformulation of the present invention and commercially available preparations: The albendazole ivermectin nanoformulation prepared in Example 9 of the present invention (abbreviated as Preparation 1) and the commercially available albendazole ivermectin powder (albendazole ivermectin premix, North China Pharmaceutical Group Animal Health Products Co., Ltd.) (abbreviated as Preparation 2) were respectively formulated into 0.5 mg / mL and 0.75 mg / mL solutions, and then Caenorhabditis elegans was cultured with the prepared solutions for 24 hours (the specific experimental process refers to the insecticidal effect test of the albendazole ivermectin nanoformulation of the present invention at different concentrations above), and the Caenorhabditis elegans mortality rates of different preparations were counted. The experimental results are shown in Tables 3 and Figure 7 shown.

[0105] From Table 3 and Figure 7 It can be seen that at the concentrations of 0.5 mg / mL and 0.75 mg / mL, the Caenorhabditis elegans mortality rate of the commercially available albendazole ivermectin powder is 0%, that is, the commercially available albendazole ivermectin powder has no insecticidal effect on Caenorhabditis elegans, while the Caenorhabditis elegans mortality rates of the albendazole ivermectin nanoformulation of the present invention at concentrations of 0.5 mg / mL and 0.75 mg / mL are 24.80% and 93.86%, respectively, and the insecticidal effect on Caenorhabditis elegans is significantly better than that of the commercially available preparations. Therefore, the albendazole ivermectin nanoformulation of the present invention has a good insecticidal effect on Caenorhabditis elegans.

[0106] Although preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. Those skilled in the art will be able to conceive of multiple variations, changes and substitutions without departing from the present invention. It should be understood that the various alternatives to the embodiments of the present invention described herein can be used to implement the present invention. It is intended that the scope of the present invention be limited to the appended claims, and that methods and structures and equivalents thereof within the scope of these claims are covered thereby.

Claims

1. An albendazole ivermectin nanoformulation, which is composed of the following components by weight composition: Albendazole: 10 parts Ivermectin: 0.3-1 part Dispersant: 53-111 parts Wherein, albendazole and ivermectin account for 8.87-16.27% of the total weight of the albendazole ivermectin nanoformulation, the dispersant is a mixture of tannic acid, sodium phytate and sodium dodecylbenzene sulfonate, and the weight ratio of tannic acid, sodium phytate and sodium dodecylbenzene sulfonate in the dispersant is 30-90:1-10:20, The preparation method of the albendazole ivermectin nano preparation comprises the following steps: Step a: at room temperature, albendazole and ivermectin are mixed, then added into a solvent to dissolve, and a solubilizing agent is added to obtain a mixed solution A; Step b: dissolving the dispersant in water to obtain a mixed solution B; Step c: under shear conditions, adding the mixed solution A dropwise to the mixed solution B to obtain a mixed solution C; Step d: centrifuging and drying the mixed solution C to obtain an albendazole-ivermectin nanoformulation. The step c comprises: using a high-speed shearing machine to shear the mixed solution B at 10000-15000 rpm for 5 min, and at the same time, dripping the mixed solution A into the mixed solution B at a speed of 2 mL / min; The step d comprises: subjecting the mixed solution C to high-speed centrifugation separation at a speed of 8000-12000 rpm for 20 minutes to obtain a precipitate, and freeze-drying the precipitate at -30°C to -50°C for 48-96 hours to obtain an albendazole ivermectin nanoformulation.

2. The albendazole ivermectin nanoformulation according to claim 1, It is characterized in that The albendazole ivermectin nano preparation is composed of the following components by weight: Albendazole: 10 parts Ivermectin: 0.5-0.8 parts Dispersant: 80-111 parts Among them, albendazole and ivermectin account for 8.87-12.09% of the total weight of the albendazole ivermectin nano preparation, and in the dispersant, the weight ratio of tannic acid, sodium phytate and sodium dodecylbenzene sulfonate is 50-70:3-7:

20.

3. The albendazole ivermectin nanoformulation according to claim 2, It is characterized in that The albendazole ivermectin nano preparation is composed of the following components by weight: Albendazole: 10 parts Ivermectin: 0.7 parts Dispersant: 90 parts Among them, albendazole and ivermectin account for 10.63% of the total weight of the albendazole ivermectin nano preparation, and in the dispersant, the weight ratio of tannic acid, sodium phytate and sodium dodecylbenzene sulfonate is 65:5:

20.

4. The albendazole ivermectin nanoformulation according to claim 1, It is characterized in that The albendazole-ivermectin nano preparation is a water-soluble powder with a particle size of 30-80 nm.

5. The preparation method of the albendazole ivermectin nanoformulation according to any one of claims 1 to 4, wherein the preparation method The following steps are involved: Step a: at room temperature, albendazole and ivermectin are mixed, then added into a solvent to dissolve, and a solubilizing agent is added to obtain a mixed solution A; Step b: dissolving the dispersant in water to obtain a mixed solution B; Step c: under shear conditions, adding the mixed solution A dropwise to the mixed solution B to obtain a mixed solution C; Step d: centrifuging and drying the mixed solution C to obtain an albendazole-ivermectin nanoformulation. The step c comprises: using a high-speed shearing machine to shear the mixed solution B at 10000-15000 rpm for 5 min, and at the same time, dripping the mixed solution A into the mixed solution B at a speed of 2 mL / min; The step d comprises: subjecting the mixed solution C to high-speed centrifugation separation at a speed of 8000-12000 rpm for 20 minutes to obtain a precipitate, and freeze-drying the precipitate at -30°C to -50°C for 48-96 hours to obtain an albendazole ivermectin nanoformulation.

6. The preparation method according to claim 5, It is characterized in that The solvent in step a is anhydrous ethanol or γ-valerolactone, the solubilizer is glacial acetic acid, the concentration of albendazole in the mixed solution A is 0.071-0.125 g / mL; the concentration of ivermectin in the mixed solution A is 0.0038-0.0071 g / mL; The concentration of the dispersant in the mixed solution B is 0.106-0.222 g / mL.

7. The preparation method according to claim 6, It is characterized in that The concentration of albendazole in the mixed solution A is 0.091 g / mL; the concentration of ivermectin in the mixed solution A is 0.0064 g / mL; The concentration of the dispersant in the mixed solution B is 0.180 g / mL.

8. The preparation method according to claim 5, It is characterized in that The step c comprises: using a high-speed shearing machine to shear the mixed solution B at 11000-14000 rpm for 5 min, and at the same time, dripping the mixed solution A into the mixed solution B at a speed of 2 mL / min; The step d comprises: subjecting the mixed solution C to high-speed centrifugation separation at a speed of 10000-12000 rpm for 20 minutes to obtain a precipitate, and freeze-drying the precipitate at -35°C to -45°C for 60-80 hours to obtain an albendazole ivermectin nanoformulation.

9. The preparation method according to claim 8, It is characterized in that The step c comprises: using a high-speed shearing machine to shear the mixed solution B at 12000 rpm for 5 minutes, and at the same time, dripping the mixed solution A into the mixed solution B at a speed of 2 mL / min; The step d comprises: subjecting the mixed solution C to high-speed centrifugation at a speed of 12000 rpm for 20 minutes to obtain a precipitate, and freeze-drying the precipitate at -45°C for 72 hours to obtain an albendazole ivermectin nanoformulation.